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CTO target vessel
RCA (%) 57.4
LCx (%) 21.3
LAD (%) 18.0
LM/graft (%) 3.3
Prior failed attempt for CTO PCI (%) 10
Dual injection used (%) 69
Intervention Approach
Antegrade only (%) 54.1
Antegrade followed by retrograde (%) 34.5
Primary retrograde (%) 11.4
Retrograde crossing Technique (n16)
Reverse CART (%) 69
Retrograde true to true lumen (%) 25
Just marker (%) 6
Collateral used (27 patients)
Septal (%) 73
Epicardial (%) 27
Number of approach changes for all patients (n61) 2.81.7
No. of approach changes for those with switch (n28) 3.81.4
Procedure time to cross CTO lesion (min)* 60 53
Fluoroscopy time to cross CTO lesion (min)* 23 21
Radiation exposure to cross CTO lesion (Gray) 2.54.3
Total procedure time (min)* 153 77
Total fluoroscopy time (min)* 43 26
Total radiation exposure (Gray)* 4.6 2.1
Total contrast volume (ml)* 382 152
Number of wires used* 118
Number of microcatheters used* 2.5 1.4
Number of balloons used* 5.02.5
Number of stents used* 3.01.5
Conclusions: In the “hybrid approach” to CTO intervention, multiple changes in the
crossing approach are needed in approximately half the patients, with a high overall
procedural success rate.
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Background: The aim of this study is to compare the safety and efficacy of Sirolimus
(SES), Paclitaxel (PES), Zotarolimus (ZES-R/ Endeavor Resolute), BiolimusA9 (BES),
EPC capture (ECS) and Everolimus-eluting stent (EES) on the outcome of patients with
chronic total occlusion (CTO).
Methods: A prospective analysis of 1576 patients with 1738 CTOs (396 SES, 526 PES,
219 ZES-R, 209 BES, 148 ECS, 240 EES) in six high volume Asian centers after
successful recanalization of CTO was performed. The study endpoints were 30 days and
12 and 36 months major adverse cardiac events (MACE) and target lesion revascular-
ization (TLR).
Results: See table for clinical results.
Conclusions: The use of drug-eluting stents in patients with CTO was safe with low
acute complication. Patients treated with 2nd generation DES such as ZES-R, BES and
EES showed lesser rate of restenosis compared with 1st generation drug-eluting stents.
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Background: To evaluate the long-term efficacy of Sirolimus (SES), Paclitaxel (PES),
Everolimus (EES) and Zotarolimus-eluting stent (ZES-R/ Endeavor Resolute) on the
outcome of patients with chronic total occlusions (CTO).
Methods: A total of 378 patients with 414 CTO lesions (male 72.8%, mean age 69.9 yrs,
LAD 49.5%, LCX 21.0%, RCA 26.6%, Others 2.9%) were treated with SES (102 patients
118 lesions, lesion length 36.112.9mm, stent length 41.715.6mm), PES (108 patients
114 lesions, 38.512.8mm, 43.919.5mm), EES (88 patients 94 lesions, 34.213.8mm,
40.114.8mm) and ZES-R (80 patients 88 lesions, 37.113.9mm, 42.317.3mm)
respectively. We conducted follow-up coronary angiogram and evaluated late loss in all
patients after successful implantation of SES, PES, EES and ZES-R (9, 12, 18, 24, 36
months respectively).
Results: See table for clinical results.
Conclusions: There is a different timing of late catch up phenomenon (late lumen loss)
of SES, PES, EES and ZES-R (SES: 12-18 months, PES: 9-12 months, EES: 12-18
months and ZES-R: 12-24 months) after successful implantation of SES, PES, EES and
ZES-R in patients with chronic total occlusion. Patients treated with SES, EES and ZES-R
showed lesser loss of minimum lumen diameter compared with PES.
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